It is well established that unopposed estrogen, either endogenous or therapeutic, can
induce endometrial hyperplasia and potentially endometrial cancer (EC). Anovulatory …

Introduction Epidemiological studies have shown that some hormonal contraceptive
methods are associated with increased breast cancer risk, especially if used over long …

Purpose The intention of this systematic review was to analyze the literature on breast
cancer (BC) and the use of the levonorgestrel-releasing intrauterine system (LNG-IUS) …

The possibility that the use of hormonal contraceptives may increase the risk of breast
cancer has been raised since many years. In the past this hypothesis has been dismissed …

Simple Summary Ductal carcinoma in situ (DCIS) is recognised as a precursor to invasive
breast cancer (IBC), while lobular carcinoma in situ (LCIS) is considered a risk factor for …

The recent Danish cohort study reported a 20% increased risk of breast cancer among
current and recent hormonal contraception users. These results are largely consistent with …

It is well established that unopposed estrogen for hormone therapy in postmenopausal
women (MHT) induces a dose-related stimulation of the endometrium associated with an …

To map and assess evidence regarding use of the levonorgestrel-releasing intrauterine
system (LNG-IUS) and its association with breast cancer, we conducted a systematic review …

Objectives Levonorgestrel intrauterine sustained release system (LNG-IUS) is an
intrauterine hormonal contraceptive device. Breast cancer (BC) was the most common type …

Several factors must be taken into consideration regarding the risk of breast cancer
associated with hormonal contraceptive use. Contraceptive benefits related to preventing …